Not long ago, biotechnology students had the opportunity to attend an open lecture organized by the Ukrainian pharmaceutical company “Farmak” — an undisputed leader in the pharmaceutical market of Ukraine and an active player on the international stage.
In the first part of the event, an overview of the company’s activities was presented. Farmak exports its products to more than 60 countries worldwide, has a full production cycle, and meets the highest quality standards – GMP and FDA. Currently, the company has more than 400 product dossiers in its portfolio, with 6 production facilities operational and another in the process of launch. Over the past five years, the company has paid more than 4.2 billion UAH in taxes, actively implements automation and digitalization systems, and supports employees through social guarantees and opportunities for individual professional development. In particular, among educational and career initiatives are the “FarmakLab” and “Pro Future” programs.
The second part of the presentation was devoted to the technological aspects of pharmaceutical production, specifically the topic of validation and qualification of technological processes in accordance with GMP requirements (Annex 15 “Qualification and Validation”).
Questions were discussed regarding the manufacturing process of solid dosage forms. The life cycle of the process can be described stage by stage:
• Stage 1 – pharmaceutical development;
• Stage 2 – process validation;
• Stage 3 – ongoing process verification.
During the second stage of the event, students were able to learn much interesting and useful information about validation and revalidation processes and their types. Thus, validation can be prospective or concurrent, while revalidation can be: scheduled or unscheduled (in case of changes/deviations in the technological process). Scheduled revalidation may not be conducted if:
– initial validation is complete;
– process verification has been implemented.
Regarding ongoing process verification, it is documented evidence that during serial production the process remains in a controlled state. Accordingly, the concepts of OOS (Out of Specification) and OOT (Out of Trend) were discussed, which denote deviations in the corresponding graphs from the obtained quality control results. In other words, control charts play a key role in ongoing process verification procedures. In fact, it is a “living quality control system”.
The event was extremely informative and useful for both students and faculty, as it provided an opportunity to become familiar with the essential aspects of modern pharmaceutical production. At the end of the meeting, all interested participants had the opportunity to ask interesting questions and receive substantive answers from the lecturers.
We look forward to the next meetings at #Farmak_Lab!










